Pharmicell, a biomaterials company, announced on October 29 that it will participate in 'CPHI Frankfurt 2025,' which is being held in Frankfurt, Germany until October 30, to strengthen cooperation with global clients.
CPHI is the world's largest exhibition encompassing the entire pharmaceutical and bio value chain. This year, approximately 62,000 visitors, more than 2,400 exhibiting companies, and participants from over 166 countries are expected to attend.
Pharmicell is operating a booth in the Korea Pavilion, showcasing methoxypolyethylene glycol (mPEG) and nucleoside as its main products. In addition, the company will present its portfolio of nucleic acid materials, including deoxynucleoside triphosphate (dNTP), nucleoside triphosphate (NTP), and a newly developed nucleoside lineup, to meet the research and production needs of global customers.
On-site business meetings will also be significantly expanded. Pharmicell will hold one-on-one meetings with companies such as UCB, Merck, and Yamasa. The company also expects to continue additional consultations with global clients from the United States, Europe, and other regions.
A Pharmicell representative stated, "As the global pharmaceutical and bio industries are rapidly reorganizing, this exhibition will serve as an important platform for Pharmicell to expand its global network and showcase the technological competitiveness of its key materials." The representative added, "We will further strengthen long-term supply and joint development partnerships with major partners."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
